Vistagen Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
VTGN$0.18+12.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and par value amounts)
| September 30,2025 | March 31,2025 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $62,786 | $67,131 |
| Marketable securities | 14,389 | 13,351 |
| Prepaid expenses and other current assets | 1,759 | 1,594 |
| Total current assets | 78,934 | 82,076 |
| Property and equipment, net | 516 | 476 |
| Right-of-use asset - operating lease | 1,074 | 1,335 |
| Other assets | 405 | 454 |
| Total assets | $80,929 | $84,341 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,831 | $653 |
| Accrued expenses | 8,417 | 8,810 |
| Note payable | 658 | — |
| Deferred revenue - current portion | 2,141 | 2,588 |
| Operating lease obligation - current portion | 597 | 561 |
| Total current liabilities | 13,644 | 12,612 |
| Deferred revenue - non-current portion | 336 | 391 |
| Operating lease obligation - non-current portion | 610 | 948 |
| Total liabilities | 14,590 | 13,951 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2025 and March 31, 2025; no shares outstanding at September 30, 2025 and March 31, 2025 | — | — |
| Common stock, $0.001 par value; 325,000,000 shares authorized at September 30, 2025 and March 31, 2025; 38,895,568 and 29,001,481 shares issued at September 30, 2025 and March 31, 2025, respectively | 39 | 29 |
| Additional paid-in capital | 512,398 | 481,956 |
| Treasury stock, at cost, 4,522 shares of common stock held at September 30, 2025 and March 31, 2025 | (3,968) | (3,968) |
| Accumulated other comprehensive income | 14 | 5 |
| Accumulated deficit | (442,144) | (407,632) |
| Total stockholders’ equity | 66,339 | 70,390 |
| Total liabilities and stockholders’ equity | $80,929 | $84,341 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.